Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Targeted Treatment for Advanced Non-Small Cell Lung Cancer that Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

Trial Status: active

This phase II Expanded Lung-MAP treatment trial tests how well amivantamab hyaluronidase works in treating patients with MET amplification non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Amivantamab hyaluronidase is a drug that reduces extra copies of the MET gene, a change present in your tumor. Giving amivantamab hyaluronidase may lower the chance of the growth or spread of advanced non-small cell lung cancer that has extra copies of the MET gene in the tumor.